- Home
- SW vs RPRX Comparison
SW vs RPRX Comparison
Compare SW & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SW | RPRX |
|---|---|---|
| Founded | 1934 | 1996 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 16.4B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SW | RPRX |
|---|---|---|
| Price | $38.33 | $39.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $53.55 | $45.75 |
| AVG Volume (30 Days) | ★ 5.1M | 3.7M |
| Earning Date | 02-11-2026 | 02-10-2026 |
| Dividend Yield | ★ 4.52% | 2.24% |
| EPS Growth | ★ 109.82 | N/A |
| EPS | 1.42 | ★ 1.75 |
| Revenue | ★ $31,138,000,000.00 | $2,349,844,000.00 |
| Revenue This Year | $52.96 | $37.66 |
| Revenue Next Year | $2.73 | $2.34 |
| P/E Ratio | $26.84 | ★ $22.41 |
| Revenue Growth | ★ 89.50 | 3.70 |
| 52 Week Low | $32.73 | $25.02 |
| 52 Week High | $56.05 | $41.24 |
Technical Indicators
Market Signals| Indicator | SW | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.63 | 55.87 |
| Support Level | $37.53 | $38.20 |
| Resistance Level | $38.35 | $39.50 |
| Average True Range (ATR) | 0.83 | 0.68 |
| MACD | 0.23 | 0.03 |
| Stochastic Oscillator | 88.18 | 76.41 |
Price Performance
Historical ComparisonAbout SW Smurfit WestRock plc Ordinary Shares
Smurfit WestRock manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. After the merger of Smurfit Kappa and WestRock in summer 2024, Smurfit WestRock became the largest producer of containerboard in the world, with substantial operations in North America, South America, and Europe.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.